Welcome to ActivSignal
ActivSignal is an oncology diagnostic company developing an early detection assay for pancreatic cancer.
Our mission is to improve cancer outcomes by detecting cancer earlier, when it can still be treated.
Company
At ActivSignal, we are focused on developing better assays for early cancer detection. Our technology for profiling proteins and other non-DNA biomarkers identifies multi-target bio-signatures in patient samples, offering a highly specific and sensitive platform for early cancer detection. Our team is comprised of experienced scientists dedicated to advancing cancer diagnostics and improving patient outcomes.
Technology
Multiplex Biomarker Quantification
​
ActivSignal’s Multiplex Paired-Antibody Amplified Detection (MPAD) technology is a highly specific and sensitive platform for profiling proteins and other non-DNA biomarkers in multiplex.
​​
MPAD detects the protein targets using specific, dual-binding of antibody pairs, patented architecture that increases specificity, signal amplification, and specific NGS read-out--with a large and tunable dynamic range. Hundreds of biomarkers can be measured in multiplex from the same <5uL sample with high specificity and sensitivity.
Approach
Earlier Cancer Detection
​​
The MPAD read-out from the patient sample, across the multiple proteins and other biomarkers in the Panel, is used to create a “bio-signature” for that individual.
​​
AI is then harnessed to match this bio-signature against the subtle signatures of early-stage cancer and other related conditions, in order to generate a diagnosis.
​​
The combination of high specificity and sensitivity, applied to biologically important biomarkers, even those in lower abundance, and in multiplex, enables the detection of cancer at an earlier stage.
Recognition
ActivSignal's work has been supported by multiple grant awards from the National Science Foundation and the MassVentures START program.
